- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04870047
Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation (COATING)
March 12, 2024 updated by: Phenox GmbH
To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
170
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elisabeth Demant-Bauchspiess
- Phone Number: +49 (0)173 3099117
- Email: COATING@wallabyphenox.com
Study Contact Backup
- Name: Katarzyna Dudar
- Phone Number: 1744 +49 234 36 919
- Email: COATING@wallabyphenox.com
Study Locations
-
-
-
Bordeaux, France, 33076
- Recruiting
- CHU Bordeaux
-
Contact:
- Xavier Barreau, Dr.
-
Le Kremlin-Bicêtre, France, 94270
- Recruiting
- Hôpital Bicêtre
-
Contact:
- Laurent Spelle, Prof.
-
Lyon, France, 69002
- Recruiting
- Chu de Lyon
-
Contact:
- Omer Eker, Prof.
-
Marseille, France, 13005
- Not yet recruiting
- Marseille University Hospital Timone
-
Contact:
- Jean-François Hak, Dr.
-
Montpellier, France, 34090
- Suspended
- CHU de Montpellier
-
Reims, France, 51092
- Completed
- CHU Reims - Hôpital Maison Blanche
-
Toulouse, France, 31059
- Withdrawn
- CHU Toulouse
-
-
-
-
-
Augsburg, Germany, 86156
- Active, not recruiting
- Universitatsklinikum Augsburg
-
Erfurt, Germany, 99089
- Recruiting
- Helios Klinikum Erfurt
-
Contact:
- Joachim Klisch, Prof.
-
Halle, Germany, 06120
- Recruiting
- Universitatsklinikum Halle (Saale)
-
Contact:
- Stefan Schob, Dr. med.
-
München, Germany, 81377
- Recruiting
- Klinikum der LMU München
-
Contact:
- Thomas Liebig, Prof. Dr.
-
Nürnberg, Germany, 90471
- Recruiting
- Klinikum Nürnberg Süd
-
Contact:
- Markus Holtmannspötter, Dr.
-
Recklinghausen, Germany
- Recruiting
- Klinikum Vest Recklinghausen
-
Contact:
- Christian Loehr, Dr. med.
-
Stuttgart, Germany, 70174
- Recruiting
- Klinikum Stuttgart
-
Contact:
- Victoria Hellstern, Dr.
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Withdrawn
- Universitatsklinikum Leipzig
-
-
-
-
-
Jerusalem, Israel, 9112001
- Recruiting
- Hadassah University Medical Center
-
Contact:
- Jose Cohen, Dr.
-
-
-
-
-
Milan, Italy, 20133
- Recruiting
- Fondazione I.R.C.C.S. Instituto Neurologico Carlo Besta
-
Contact:
- Elisa Francesca Maria Ciceri, Dr.
-
-
-
-
-
Košice, Slovakia, 04190
- Recruiting
- UNLP Košice
-
Contact:
- Piotr Pedowski, MUDr.
-
-
-
-
-
Basel, Switzerland, 4051
- Recruiting
- Universitatsspital Basel
-
Contact:
- Marios-Nikos Psychogios, Prof. Dr.
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Recruiting
- Queen Elisabeth Hospital Birmingham
-
Contact:
- Saleh Lamin, Dr.
-
Edinburgh, United Kingdom
- Recruiting
- Western General Hospital
-
Contact:
- Peter Keston, Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At least 18 years of age.
- Subject has a saccular, unruptured or recanalized intracranial aneurysm. The subject may also have a previous ruptured aneurysm, provided rupture of this aneurysm 30 days from the index procedure.
- Subject is intended to be treated for only one target aneurysm during the index procedure except for segmental disease (multiple aneurysms located on the same arterial segment aimed to be treated with one investigational device or investigational telescopic devices).
- Subject has already been selected for flow diversion therapy as the appropriate treatment.
- Subject has a mRS ≤ 2 before the procedure, as determined by a certified assessor independent of the index procedure.
- Subject is able to understand the patient information and provides written informed consent verifying the use of his/her data (according to data protection laws).
Exclusion Criteria:
- Subject who is currently prescribed under any long lasting antiplatelet and/or anticoagulation medication.
- Subject has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
- Subject has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedure.
- Subject with target aneurysm previously treated with a stent or flow diverter.
- Subject is expected to be treated for another aneurysm during the 30 days following the index procedure.
- Subject with a confirmed stenosis in parent artery.
- Subject with a blister-like aneurysm, fusiform aneurysm, dissecting aneurysm or aneurysm associated with a brain arteriovenous malformation (AVM).
- Subject has a pre-procedure mRS >2.
- Any known contraindication to treatment with the p64 MW HPC Flow Modulation Device in accordance with device IFU.
- Subject who has undergone stenting of the ipsilateral carotid artery within 3 months of the index procedure.
- Known serious sensitivity to radiographic contrast agents.
- Known sensitivity to nickel, titanium metals, or their alloys.
- Subject already enrolled in other clinical trials (including COATING study) that would interfere with study endpoints.
- Known renal failure as defined by a serum creatinine > 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) < 30.
- Subject who has a contraindication to MRI or angiography for whatever reason.
- Subject with a comorbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments.
- Subject with any known allergy to heparin, ASA or other antiplatelet medications.
- Subject with coagulation disorder
- Pregnant woman or breast feeding.
- Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: p64 MW HPC Flow Diverter + SAPT
|
Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
|
Experimental: p64 MW Flow Diverter + DAPT
|
Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of DWI lesions
Time Frame: 48 hours (± 24 hours)
|
Number of diffusion-weighted imaging (DWI) lesions within 48 hours (+/- 24 hours) of the index procedure visualized via MRI.
|
48 hours (± 24 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term morbi-mortality rate
Time Frame: 30 days (± 7 days)
|
Morbi-mortality rate at 30 days assessed by mRS > 2
|
30 days (± 7 days)
|
Rate of neurological death or major stroke
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of neurological death or major stroke (ischemic or hemorrhagic, defined as an increase of 4 or more points according to the National Institute of Health Stroke Scale Score) in the territory supplied by the treated artery, as assessed by the Clinical Events Committee
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Long-term morbi-mortality rate
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of subjects who have a mRS decline to a score of 3 or more (mRS > 3), or an increase of 2 points from baseline mRS score, as assessed by the Clinical Events Committee
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of subjects with dissusion-weighted imaging (DWI) lesions
Time Frame: 48 hours (± 24 hours)
|
Rate of subjects with greater than 6 diffusion-weighted imaging (DWI) lesions or territorial stroke
|
48 hours (± 24 hours)
|
Delayed aneurysm rupture
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of an intracranial hemorrhage from delayed aneurysm rupture (from the day after index procedure), as assessed by the Clinical Events Committee
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Delayed intraparenchymal hemorrhage
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of delayed intraparenchymal haemorrhage unrelated to aneurysm rupture, as assessed by the Clinical Events Committee
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of device deployment at the target site without technical complications
Time Frame: During intervention
|
Rate of device deployment at the target site without technical complications, as assessed by the site
|
During intervention
|
Rate of complete aneurysm occlusion
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of complete aneurysm occlusion using the 3-grade scale, as assessed by the Core Lab
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of target aneurysm recurrence
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of target aneurysm recurrence, as assessed by the Imaging Core Lab
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of target aneurysm retreatment
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of target aneurysm retreatment, as assessed by the Clinical Event Committee
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of intrastent stenosis and/or thrombosis at the target site
Time Frame: 180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Rate of intrastent stenosis and/or thrombosis at the target site, as assessed by the Core Lab through DSA
|
180 days (150 - 240 days) and 365 days (335 - 456 days) post procedure
|
Mean length of hospital stay
Time Frame: From admission up to discharge, assessed up to 456 days
|
Mean length of hospital stay (from hospital admission and up to hospital discharge)
|
From admission up to discharge, assessed up to 456 days
|
Rate of peripheral bleeding
Time Frame: Any event reported from discharge to 365 days (335 - 456 days) post procedure
|
Rate of peripheral bleeding, as assessed by the Clinical Events Committee
|
Any event reported from discharge to 365 days (335 - 456 days) post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Laurent Pierot, Prof. Dr., CHRU Hôpital Maison-Blanche
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 26, 2021
First Submitted That Met QC Criteria
April 30, 2021
First Posted (Actual)
May 3, 2021
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CO48/BO1309
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Aneurysm
-
University of FloridaCompletedIntracranial Aneurysm | Aneurysm, Intracranial | Giant Intracranial AneurysmUnited States
-
Centre hospitalier de l'Université de Montréal...RecruitingIntracranial Hemorrhage Ruptured AneurysmUnited States, Canada, Spain
-
Universitätsklinikum Hamburg-EppendorfRecruitingAneurysm | Aneurysm, Intracranial | Aneurysm Cerebral | Aneurysm, Brain | Aneurysm of Cerebral ArteryGermany
-
Merlin MD Pte LtdRecruitingIntracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm, LesionSpain
-
Stryker NeurovascularStryker (Beijing) Healthcare Products Co., LtdTerminated
-
Beijing Tiantan HospitalGuangzhou Red Cross Hospital; The First Dongguan Affiliated Hospital of Guangdong... and other collaboratorsRecruiting
-
Hospices Civils de LyonNot yet recruitingIntracranial Sacciform Aneurysm
-
Stryker NeurovascularActive, not recruitingAneurysm, IntracranialUnited States, Canada, Australia
-
Evasc Medical Systems Corp.WithdrawnAneurysm, Intracranial
-
Fondation Ophtalmologique Adolphe de RothschildActive, not recruitingIntracranial Aneurysms | Ruptured AneurysmFrance
Clinical Trials on Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device
-
Shanghai Wallaby Medical Technologies Co.,Inc.Phenox GmbHRecruitingIntracranial AneurysmChina